Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16

Journal of Infectious Diseases

Volumn 208, Issue 3, 2013, Pages 403-412

  Moscicki, Anna Barbara ^a   Ma, Yifei ^a   Farhat, Sepideh ^a   Darragh, Teresa M ^b   Pawlita, Michael ^c   Galloway, Denise A ^d,e   Shiboski, Stephen ^b  

^a School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF WASHINGTON   (United States)

^e SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

reactivation; redetection of HPV16; risk for acquisition; risk for clearance

Indexed keywords

MEDROXYPROGESTERONE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FEMALE GENITAL TRACT CYTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REPEAT PROCEDURE; SEROLOGY; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL LAVAGE; VIRAL CLEARANCE;

REACTIVATION; REDETECTION OF HPV16; RISK FOR ACQUISITION; RISK FOR CLEARANCE;

ADOLESCENT; ANTIBODIES, VIRAL; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; RECURRENCE; RISK FACTORS; YOUNG ADULT;

EID: 84880230016     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit175     Document Type: Article

References (30)

1. Syrjanen K, Hakama M, Saarikoski S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis 1990; 17:15-9.
2. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011; 121:4593-9.
3. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202:1789-99.
4. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010; 70:8569-77.
5. Rodriguez AC, Schiffman M, Herrero R, et al. Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithe-lial neoplasia grade 2/3. Int J Cancer 2012; 131:1874-81.
6. Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serologi-cal assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011; 204:94-102.
7. Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011; 20:699-707.
8. Lin SW, Ghosh A, Porras C, et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One 2013; 8:e53067.
9. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer 2009; 19:508-12.
10. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-84.
11. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squa-mous intra-epithelial lesions in young women. Lancet 2004; 364:1678-83.
12. Scott ME, Ma Y, Farhat S, Shiboski S, Moscicki AB. Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol 2006; 26:222-32.
13. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papil-lomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285:2995-3002.
14. Moscicki AB, Ma Y, Jonte J, et al. The role of sexual behavior and human papillomavirus persistence in predicting repeated infections with new human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2010; 19:2055-65.
15. Rowhani-Rahbar A, Carter JJ, Hawes SE, et al. Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis 2009; 200:1452-5.
16. Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007; 16:1874-9.
17. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavi-rus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005; 51:1845-53.
18. Antonsson A, Green AC, Mallitt KA, et al. Prevalence and stability of antibodies to 37 human papillomavirus types-a population-based longitudinal study. Virology 2010; 407:26-32.
19. Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog 2008; 4:e1000091.
20. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102:315-24.
21. Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010; 115:1150-8.
22. WHO Collaborative Study. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1992; 45:299-312.
23. Ruutu M, Wahlroos N, Syrjanen K, Johansson B, Syrjanen S. Effects of 17beta-estradiol and progesterone on transcription of human papillo-mavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J Gynecol Cancer 2006; 16:1261-8.
24. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillo-mavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-9.
25. Lieberman JA, Moscicki AB, Sumerel JL, Ma Y, Scott ME. Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clin Vaccine Immunol 2008; 15:49-54.
26. Malik ZA, Hailpern SM, Burk RD. Persistent antibodies to HPV viruslike particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 2009; 22:445-9.
27. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18 infections. J Natl Cancer Inst 2010; 102:1653-62.
28. Berg CJ, Painter JE, Sales JM, et al. Smoking as a risk factor for STI diagnosis among African American females. Am J Health Behav 2012; 36:505-12.
29. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervi-covaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186:737-42.
30. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13:324-7.